Skip to main content
SpringerLink
Log in

Summary of Safety of Vasovist® at 0.03 mmol/kg Body Weight Dose — Clinical Data

  • Chapter
Clinical Blood Pool MR Imaging

  • 547 Accesses

Abstract

The first gadolinium-containing contrast-enhancing agent for magnetic resonance imaging (MRI) — Magnevist® (Gd-DTPA, Bayer Schering Pharma AG, Berlin, Germany), — was introduced in 1988 [1, 2]. Today a variety of different Gd-based contrast agents (GBCAs) are available for clinical use, and they have become a standard part of the radiologist’s diagnostic repertoire.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Claussen C, Laniado M, Schörner W, et al (1985) Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. Am J Neuroradiol 6:669–674

    PubMed  CAS  Google Scholar 

  2. Niendorf HP, Laniado M, Semmler W, Schorner W, Felix R (1987) Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. Am J Neuroradiol 8:803–815

    PubMed  CAS  Google Scholar 

  3. Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576. Review. Erratum in (2007) Fundam Clin Pharmacol 21:335

    Article  PubMed  Google Scholar 

  4. Cacheris WP et al (1990) The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8:467–481

    Article  PubMed  CAS  Google Scholar 

  5. White DH et al (1991) The thermodynamics of complexation of lanthanide (III) DTPA-bisamide complexes and their implication for stability and solution structure. Invest Radiol 126 [Suppl 1]:S226–S228

    Google Scholar 

  6. Schmitt-Willich H, Brehm M, Ewers CL, et al (1999) Synthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem 38:1134–1144

    Article  PubMed  CAS  Google Scholar 

  7. Uggeri F et al (1995) Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its LN(III) complexes (Ln-Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-(4-carboxy-5,8,11-tris(carboxamethyl)-I-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)) gadolinite(2-) in a mixture with its enantiomer. Inorg Chem 34:633–642

    Article  CAS  Google Scholar 

  8. Caravan P et al (2001) Thermodynamic stability and kinetic inertness of MS-325, a new blood-pool agent for magnetic resonance imaging. Inorg Chem 40:2170–2176

    Article  PubMed  CAS  Google Scholar 

  9. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715–724

    Article  PubMed  Google Scholar 

  10. Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10:477–484

    Article  PubMed  CAS  Google Scholar 

  11. Knopp MV, Balzer T, Esser M, Kashanian F, Paul P, Niendorf HP (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41:491–499

    Article  PubMed  Google Scholar 

  12. Prince MR, Erel HE, Lent RW, et al (2003) Gadodiamide administration causes spurious hypocalcemia. Radiology 227:639–646

    Article  PubMed  Google Scholar 

  13. Choyke PL, Knopp MV (2003) Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology 227:627–628

    Article  PubMed  Google Scholar 

  14. Emerson J, Kost G (2004) Spurious hypocalcemia after Omniscanor Optimark-enhanced magnetic resonance imaging. Arch Pathol Lab Med 128:1151–1156

    PubMed  CAS  Google Scholar 

  15. Moore CD, Newman RC, Caridi JG (2006) Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: A case report and review of the literature. Rev Urol 8:165–168

    PubMed  Google Scholar 

  16. Zhang HL, Ersoy H, Prince MR (2006) Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium and creatinine measurements. J Magn Res Imaging 23:383–387

    Article  Google Scholar 

  17. Löwe A, Balzer T, Hirt U (2005) Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol 40:521–525

    Article  PubMed  Google Scholar 

  18. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352

    Article  PubMed  CAS  Google Scholar 

  19. Kang HP, Scott MG, Joe BN, Narra V, Heiken J, Parvin CA (2004) Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. Clin Chem 50:741–746

    Article  PubMed  CAS  Google Scholar 

  20. Grobner T (2006) Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 11 (epub ahead of print)

    Google Scholar 

  21. Marckmann P, Skov L, Rossen K, et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362

    Article  PubMed  Google Scholar 

  22. Maloo M, Abt P, Kashyap R, et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplan 6:2212

    Article  CAS  Google Scholar 

  23. Thomsen HS, Morcos SK, Dawson P (2006) Is there a causal relation between the administration of gadolinium-based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61:905–906

    Article  PubMed  CAS  Google Scholar 

  24. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264–267

    Article  PubMed  Google Scholar 

  25. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188:586–592

    Article  PubMed  Google Scholar 

  26. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42:139–145

    Article  PubMed  Google Scholar 

  27. Sadowski EA, et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157

    Article  PubMed  Google Scholar 

  28. Goyen M, Edelman M, Perreault P, et al (2005) MR angiography of aortoiliac ocdusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236:825–833

    Article  PubMed  Google Scholar 

  29. Rapp JH, Wolff SD, Quinn SF, et al (2005) Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of Gadofosveset-enhanced MR angiography — multicenter comparative phase III study. Radiology 236:71–78

    Article  PubMed  Google Scholar 

  30. European Medicines Agency (2006) Vasovist: summary of product characteristics. [online]. Available from URL: http://www.emea. eu.int/

    Google Scholar 

  31. European Medicines Agency. Vasovist: Scientific discussion. [online] (2007). Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/vasovist/vasovist.htm

    Google Scholar 

  32. Henness S, Keating GM. (2006) Gadofosveset. Drugs 66:851–857

    Article  PubMed  CAS  Google Scholar 

  33. Shamsi K, Yucel EK, Chamberlin P (2006) A summary of safety of Gadofosveset (MS-325) at 0.03 mmol Gd/kg body weight dose. Invest Radiol 41:822–830

    Article  PubMed  CAS  Google Scholar 

  34. Ref.: ClinicalTrails.gov. [online] (2007). Available from URL http://www.clinicaltrials.gov

    Google Scholar 

  35. The Medical Dictionary for Regulatory Activities; MedDRA®. Registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) (2007). Available at: http://www.meddramsso.com/MSSOWeb/index.htm

    Google Scholar 

  36. Nelson KL, Gifford LM, Lauber-Huber C, et al (1995) Clinical safety of gadopentetate dimeglumine. Radiology 196:439–443

    PubMed  CAS  Google Scholar 

  37. Hagan JB (2004) Anaphylactoid and adverse reactions to radiocontrast agents. Immunol Allergy Clin N Am 24:507–519

    Article  Google Scholar 

  38. Cowper SE, Robins HS, Steinberg HM, Su LhD, Gupta S, Leboit PE (2000) Sderomyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001

    Article  PubMed  CAS  Google Scholar 

  39. Michaely HJ, Thomsen HS, Reiser MF, Schoenberg SO (2007) Nephrogenic systemic fibrosis (NSF) — implications for radiology. Radiologe 47:785–793

    Article  PubMed  CAS  Google Scholar 

  40. Schmitt-Willich H (2007) Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 80:581–582; author reply 584–585

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Medical Affairs Diagnostic Imaging, Bayer Schering Pharma AG, Müllerstrasse 178, 13353, Berlin, Germany

    Matthias Voth & Andrea Löwe

Authors
  1. Matthias Voth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Löwe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiology, Maastricht University Medical Center, Peter Debijelaan 25, 6229 HX, Maastricht, The Netherlands

    Tim Leiner

  2. University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany

    Mathias Goyen

  3. European Business Unit Diagnostic Imaging, Bayer Schering Pharma AG, Muellerstrasse 178, 13353, Berlin, Germany

    Martin Rohrer

  4. Department of Clinical Radiology and Nuclear Medicine University Hospital Mannheim, Medical Faculty Mannheim-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Stefan Schönberg

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Voth, M., Löwe, A. (2008). Summary of Safety of Vasovist® at 0.03 mmol/kg Body Weight Dose — Clinical Data. In: Leiner, T., Goyen, M., Rohrer, M., Schönberg, S. (eds) Clinical Blood Pool MR Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77861-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-77861-5_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-77860-8

  • Online ISBN: 978-3-540-77861-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation